1 |
NCT01991652 |
Recruiting |
Collaborative Wilms Tumour Africa Project |
|
|
Observational |
|
- VU University Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
400 |
All |
up to 18 Years (Child, Adult) |
NCT01991652 |
CollabWilmsAfrica |
|
January 2014 |
December 2017 |
December 2019 |
November 25, 2013 |
November 15, 2016 |
|
- Mbingo Mission Hospital
North West Cameroon, Cameroon - Tikur Anbessa Specialized Hospital
Addis Abeba, Ethiopia - Korle Bu Hospital
Accra, Ghana - College of Medicine
Blantyre, Malawi
|
2 |
NCT00503893 |
Recruiting |
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies |
|
- Behavioral: Questionnaire
- Other: Blood specimen
|
Observational |
|
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Genetic Events Involved in Development of Wilms' tumor, Genitourinary Anomalies, Hemihypertrophy and Beckwith-Wiedemann, and/or Aniridia
|
1500 |
All |
Child, Adult, Senior |
NCT00503893 |
P80-099 P01CA034936-23 |
|
December 1980 |
December 2018 |
December 2018 |
July 19, 2007 |
July 14, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
3 |
NCT02581384 |
Recruiting |
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors |
- Ewing Sarcoma
- Rhabdomyosarcoma
- Wilms Tumor
- (and 8 more...)
|
- Radiation: Stereotactic Body Radiotherapy (SBRT)
|
Interventional |
Phase 1 Phase 2 |
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Overall Response
- Best Overall Response
|
25 |
All |
up to 21 Years (Child, Adult) |
NCT02581384 |
15-278 |
|
May 2016 |
February 2019 |
February 2023 |
October 21, 2015 |
February 2, 2018 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
4 |
NCT02867592 |
Recruiting |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
- Adrenal Cortex Carcinoma
- Adult Alveolar Soft Part Sarcoma
- Adult Clear Cell Sarcoma of Soft Parts
- (and 30 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) parameters of cabozantinib s-malate
|
146 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02867592 |
NCI-2016-01258 ADVL1622 U10CA180886 |
|
May 8, 2017 |
November 21, 2018 |
November 21, 2018 |
August 16, 2016 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 119 more...)
|
5 |
NCT01621724 |
Recruiting |
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study |
- Acute Myeloid Leukaemia
- Chronic Myeloid Leukaemia
|
- Genetic: WT1 TCR-transduced T cells
|
Interventional |
Phase 1 Phase 2 |
- Cell Medica Ltd
- University College, London
- Cell Therapy Catapult
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Identify organ toxicities and other side effects
- Transduction efficiency and TCR expression on TCR-transduced cells
- WT1-specific immune responses of TCR-transduced T cells
|
18 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01621724 |
D-00272-CT2014001 |
|
April 2012 |
May 2019 |
October 2019 |
June 18, 2012 |
April 19, 2018 |
|
- University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom - University College London Hospitals NHS Trust
London, United Kingdom
|
6 |
NCT02550535 |
Recruiting |
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients |
- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukaemia (AML)
|
- Genetic: Gene-modified WT1 TCR-transduced T cells intravenous infusion
|
Interventional |
Phase 1 Phase 2 |
- Cell Medica Ltd
- University College, London
- Cell Therapy Catapult
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety following gene-modified WT1 TCR T cell therapy as measured by suspected unexpected serious adverse reactions (SUSARS)
- Proportion of subjects achieving one or more IWG response criteria following gene-modified WT1 TCR T cell therapy
- Safety and tolerability of gene-modified WT1 TCR therapy as measured by clinical laboratory parameters and adverse events
- (and 5 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT02550535 |
D-00272-CT2014002 |
|
September 2015 |
July 2019 |
July 2019 |
September 15, 2015 |
April 20, 2018 |
|
- AZ St Jan Brugge-Oostende AV
Brugge, Belgium - UZ Leuven
Leuven, Belgium - Uniklinikum Dresden
Dresden, Germany - (and 3 more...)
|
7 |
NCT01995708 |
Recruiting |
CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation |
|
- Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
- Other: Standard of care
|
Interventional |
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Rockefeller University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety
- Immune response monitoring
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01995708 |
13-009 |
|
January 31, 2014 |
November 2018 |
November 2018 |
November 26, 2013 |
March 21, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States - The Rockefeller University/Center for Clinical & Translational Science
New York, New York, United States
|
8 |
NCT02649829 |
Recruiting |
Autologous Dendritic Cell Vaccination in Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Biological: dendritic cell vaccination plus chemotherapy
|
Interventional |
Phase 1 Phase 2 |
- University Hospital, Antwerp
- Kom Op Tegen Kanker
- stichting tegen kanker
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of MPM patients with feasible and safe DC vaccine production
- Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame
- Objective clinical responses by tumor evaluation (clinical efficacy)
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02649829 |
CCRG13-002 |
MESODEC |
August 1, 2017 |
October 2020 |
November 2021 |
January 8, 2016 |
December 11, 2017 |
|
- Antwerp University Hospital
Edegem, Antwerp, Belgium - AZ Middelares
Ghent, Belgium - AZ Nikolaas
Sint-Niklaas, Belgium
|
9 |
NCT01686334 |
Recruiting |
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission |
|
|
Interventional |
Phase 2 |
- Zwi Berneman
- Kom Op Tegen Kanker
- stichting tegen kanker
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse rate
- Disease-free survival
- Overall survival
- (and 3 more...)
|
138 |
All |
18 Years and older (Adult, Senior) |
NCT01686334 |
CCRG12-001 |
WIDEA |
October 2012 |
July 2024 |
|
September 18, 2012 |
February 6, 2018 |
|
- ZNA Stuivenberg
Antwerp, Belgium - Antwerp University Hospital
Antwerp, Belgium - University Hospital Brussels
Brussels, Belgium - (and 5 more...)
|
10 |
NCT02982941 |
Recruiting |
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors |
- Neuroblastoma
- Rhabdomyosarcoma
- Osteosarcoma
- (and 3 more...)
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of enoblituzumab.
- Peak plasma concentration
- Number of participants that develop anti-drug antibodies
- Antitumor activity of enoblituzumab
|
112 |
All |
1 Year to 35 Years (Child, Adult) |
NCT02982941 |
CP-MGA271-04 |
|
December 2016 |
February 2020 |
February 2022 |
December 6, 2016 |
March 22, 2018 |
|
- Lucile Packard Children's Hospital, Stanford
Palo Alto, California, United States - National Cancer Institute, Center for Cancer Research
Bethesda, Maryland, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States - (and 3 more...)
|
11 |
NCT00898365 |
Recruiting |
Study of Kidney Tumors in Younger Patients |
- Clear Cell Sarcoma of the Kidney
- Congenital Mesoblastic Nephroma
- Diffuse Hyperplastic Perilobar Nephroblastomatosis
- (and 10 more...)
|
- Other: laboratory biomarker analysis
- Other: cytology specimen collection procedure
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Disease-free survival
- Overall survival
- Loss of heterozygosity (LOH testing discontinued as of April 2014)
|
5000 |
All |
up to 29 Years (Child, Adult) |
NCT00898365 |
AREN03B2 NCI-2009-00416 COG-AREN03B2 U10CA180886 U10CA098543 |
|
February 2006 |
January 2100 |
January 2100 |
May 12, 2009 |
November 29, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 228 more...)
|
12 |
NCT02770820 |
Recruiting |
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- EBV-Positive Neoplastic Cells Present
- HLA-A*0201 Positive Cells Present
- Minimal Residual Disease
|
- Biological: Aldesleukin
- Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 1 Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of adoptively transferred TCRC4-transduced CD8+ memory T cells and naive T cells in blood and bone marrow
- Evidence and nature of toxicities
- Frequencies of adoptively transferred TCRC4-transduced CD8+ T cells of the central memory and effector cells derived from the naïve pool cells in blood and bone marrow
- (and 10 more...)
|
35 |
All |
Child, Adult, Senior |
NCT02770820 |
9296 NCI-2016-00042 P01CA018029 P30CA015704 |
|
May 15, 2018 |
January 1, 2022 |
January 1, 2033 |
May 12, 2016 |
April 17, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
13 |
NCT02895412 |
Recruiting |
Infection and Tumour Antigen Cellular Therapy |
- Leukemia, Myelocytic, Acute
|
- Biological: Donor-derived WT1-CTL and P-CTL
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
20 |
All |
1 Year to 70 Years (Child, Adult, Senior) |
NCT02895412 |
INTACT-WT1 |
INTACT-WT1 |
August 2016 |
December 2020 |
December 2020 |
September 9, 2016 |
September 9, 2016 |
|
- Westmead Hospital
Westmead, Sydney, New South Wales, Australia
|
14 |
NCT01640301 |
Recruiting |
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant |
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
|
- Biological: Aldesleukin
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Anti-leukemic potential efficacy, in terms of duration of response (Arm II)
- Efficacy, in terms of relapse rate (Arm I)
- Incidence of chronic graft versus host disease (GVHD) (Arm I)
- (and 10 more...)
|
55 |
All |
Child, Adult, Senior |
NCT01640301 |
2498.00 NCI-2011-03362 2498 P01CA018029 P30CA015704 |
|
December 6, 2012 |
October 1, 2020 |
October 1, 2030 |
July 13, 2012 |
January 19, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
15 |
NCT02536183 |
Recruiting |
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors |
- Pediatric Cancer
- Solid Tumors
- Rhabdomyosarcoma
- (and 7 more...)
|
- Device: Magnetic resonance high intensity focused ultrasound
- Drug: Lyso-thermosensitive liposomal doxorubicin
|
Interventional |
Phase 1 |
- AeRang Kim
- Children's Research Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of LTLD
- Toxicity profile of LTLD
- Pharmacokinetics of LTLD
- (and 4 more...)
|
34 |
All |
up to 30 Years (Child, Adult) |
NCT02536183 |
HIFU Thermodox |
|
October 2016 |
October 2018 |
October 2020 |
August 31, 2015 |
April 2, 2018 |
|
- Children's National Medical Center
Washington, District of Columbia, United States
|
16 |
NCT02076906 |
Recruiting |
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors |
- Relapsed Pediatric Solid Tumors
- Refractory Pediatric Solid Tumors
- Tumors Located in Bone or Soft Tissue in Close Proximity to Bone
- (and 8 more...)
|
- Device: Magnetic Resonance High Intensity Focused Ultrasound
|
Interventional |
Phase 1 |
- AeRang Kim
- Children's Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity
- Disease response
- Patient reported outcomes and quality of life measurements
- Immune Markers
|
14 |
All |
up to 30 Years (Child, Adult) |
NCT02076906 |
HIFU3917 |
|
April 2014 |
January 2019 |
January 2019 |
March 4, 2014 |
April 3, 2018 |
|
- Children's National Medical Center
Washington, District of Columbia, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
17 |
NCT02846038 |
Recruiting |
Understanding Communication in Healthcare to Achieve Trust (U-CHAT) |
- Neuroblastoma
- Sarcoma
- Carcinoma
- (and 6 more...)
|
|
Observational |
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Number of communication styles employed
|
176 |
All |
Child, Adult, Senior |
NCT02846038 |
U-CHAT |
|
September 9, 2016 |
July 31, 2019 |
July 31, 2019 |
July 27, 2016 |
September 13, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
18 |
NCT03382158 |
Recruiting |
International PPB Registry for PPB, DICER1 and Associated Conditions |
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- (and 10 more...)
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Washington University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Event-free survival
- Overall response to chemotherapy
- Overall survival
- (and 4 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03382158 |
FDAAA |
|
December 6, 2016 |
December 6, 2023 |
December 6, 2026 |
December 22, 2017 |
December 22, 2017 |
|
- Children;s Minnesota
Minneapolis, Minnesota, United States
|
19 |
NCT01661400 |
Recruiting |
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors |
- Glioma
- Neuroectodermal Tumors, Primitive
- Wilms Tumor
- (and 4 more...)
|
- Drug: Metronomic Cyclophosphamide
- Drug: Thalidomide
|
Interventional |
Early Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Toxicity
- Radiographic marker of neovascularization
- Best overall response
|
12 |
All |
6 Months to 21 Years (Child, Adult) |
NCT01661400 |
201209088 |
ASCR |
October 2012 |
February 2018 |
February 2021 |
August 9, 2012 |
November 21, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
20 |
NCT03233204 |
Recruiting |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) determined using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival (PFS)
- Incidence of toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) of olaparib
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03233204 |
NCI-2017-00766 APEC1621H U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 28, 2017 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 63 more...)
|
21 |
NCT03220035 |
Recruiting |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 22 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Vemurafenib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Progress free survival (PFS)
- Incidence of adverse events evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03220035 |
NCI-2017-01244 APEC1621G U10CA180886 |
|
July 24, 2017 |
December 31, 2023 |
December 31, 2023 |
July 18, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 62 more...)
|
22 |
NCT03213704 |
Recruiting |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 33 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Larotrectinib
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression free survival
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213704 |
NCI-2017-01264 APEC1621A U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 66 more...)
|
23 |
NCT03213678 |
Recruiting |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: PI3K/mTOR Inhibitor LY3023414
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
144 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213678 |
NCI-2017-01249 APEC1621D U10CA180886 |
|
July 31, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 67 more...)
|
24 |
NCT03213665 |
Recruiting |
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Hodgkin Lymphoma
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- (and 46 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Tazemetostat
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) defined as complete response + partial response and assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
- Progression-free survival (PFS)
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213665 |
NCI-2017-01245 APEC1621C U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 66 more...)
|
25 |
NCT03210714 |
Recruiting |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Drug: Erdafitinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03210714 |
NCI-2017-01159 APEC1621B U10CA180886 UM1CA081457 |
|
November 6, 2017 |
December 31, 2024 |
December 31, 2024 |
July 7, 2017 |
April 19, 2018 |
|
- Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Southern California Permanente Medical Group
Downey, California, United States - (and 51 more...)
|
26 |
NCT03155620 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Procedure: Biopsy
- Procedure: Biospecimen Collection
- Drug: Ensartinib
- (and 10 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of toxicity assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Incidence of research biopsy related target toxicity
- (and 2 more...)
|
1500 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03155620 |
NCI-2017-01251 APEC1621SC U10CA180886 |
|
July 24, 2017 |
September 30, 2027 |
September 30, 2027 |
May 16, 2017 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 91 more...)
|
27 |
NCT02390843 |
Recruiting |
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors |
- Retinoblastoma
- Clear Cell Sarcoma
- Renal Cell Carcinoma
- (and 9 more...)
|
- Drug: Simvastatin
- Drug: Cyclophosphamide
- Drug: Topotecan
- Drug: Myeloid growth factor
|
Interventional |
Phase 1 |
- Emory University
- Children's Healthcare of Atlanta
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Simvastatin
- Number of Dose-Limiting Toxicities (DLTs)
- Percentage of Participants With Overall Tumor Response (Response Rate)
- (and 5 more...)
|
36 |
All |
1 Year to 29 Years (Child, Adult) |
NCT02390843 |
IRB00078790 |
AflacST1402 |
February 2015 |
February 2019 |
February 2021 |
March 18, 2015 |
August 7, 2017 |
|
- Children's Healthcare of Atlanta/Emory University
Atlanta, Georgia, United States
|
28 |
NCT02689336 |
Recruiting |
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors |
- Glioma
- Rhabdomyosarcoma
- Osteosarcoma
- (and 5 more...)
|
- Biological: Erlotinib
- Drug: Temozolomide
|
Interventional |
Phase 2 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Time to progression
- Toxicities of treatment regimen
|
30 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02689336 |
201604002 |
|
August 6, 2016 |
November 30, 2019 |
May 31, 2020 |
February 23, 2016 |
February 15, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
29 |
NCT02624388 |
Recruiting |
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) |
- Lymphoma
- Childhood Lymphoma
- Solid Tumor
- (and 13 more...)
|
- Drug: Genistein
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Time to neutrophil count recovery following myelosuppressive chemotherapy
- Serum marker levels of inflammation during cycles of chemotherapy
- Number of days that participants experience adverse events that are commonly caused by chemotherapy treatment
- (and 12 more...)
|
50 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02624388 |
17588 |
UVA-Gen001 |
August 2016 |
August 2018 |
June 2019 |
December 8, 2015 |
June 21, 2017 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
30 |
NCT02162732 |
Recruiting |
Molecular-Guided Therapy for Childhood Cancer |
- Neuroblastoma
- Medulloblastoma
- Glioma
- (and 16 more...)
|
|
Interventional |
Not Applicable |
- Giselle Sholler
- Translational Genomics Research Institute
- Dell, Inc.
- Spectrum Health Hospitals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.
- Number of Participants with Adverse Events as a Measure of Safety
- Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.
- (and 3 more...)
|
200 |
All |
13 Months to 21 Years (Child, Adult) |
NCT02162732 |
NMTRC009 |
|
June 2014 |
June 2020 |
June 2021 |
June 13, 2014 |
July 11, 2017 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Rady Children's Hospital
San Diego, California, United States - Connecticut Children's Hospital
Hartford, Connecticut, United States - (and 16 more...)
|
31 |
NCT00565903 |
Recruiting |
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
- Pleuropulmonary Blastoma
- Cystic Nephroma
- Sertoli-Leydig Cell Tumor of Ovary
- (and 7 more...)
|
|
Observational |
|
- D. Ashley Hill, M.D.
- Children's Research Institute
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma
- Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome.
|
2000 |
All |
up to 95 Years (Child, Adult, Senior) |
NCT00565903 |
05-0192 / 201012830 |
PPB |
March 2005 |
December 2018 |
December 2020 |
November 30, 2007 |
July 19, 2017 |
|
- Children's National Medical Center
Washington, D.C., District of Columbia, United States
|
32 |
NCT03050268 |
Recruiting |
Familial Investigations of Childhood Cancer Predisposition |
- Acute Leukemia
- Adenomatous Polyposis
- Adrenocortical Carcinoma
- (and 43 more...)
|
|
Observational |
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identification of novel cancer predisposing genes
|
3000 |
All |
Child, Adult, Senior |
NCT03050268 |
SJFAMILY |
SJFAMILY |
April 6, 2017 |
March 31, 2037 |
March 31, 2037 |
February 10, 2017 |
January 5, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
33 |
NCT02498665 |
Recruiting |
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies |
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Glioblastoma Multiforme
- (and 6 more...)
|
- Drug: DSP-7888 Dosing Emulsion
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)
- Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing duration of study treatment
- Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)
- (and 3 more...)
|
96 |
All |
18 Years and older (Adult, Senior) |
NCT02498665 |
BBI-DSP7888-101 |
|
November 2015 |
August 2018 |
August 2019 |
July 15, 2015 |
April 6, 2018 |
|
- USOR - Rocky Mountain Cancer Center
Denver, Colorado, United States - Emory University Winship Cancer Institute
Atlanta, Georgia, United States - Horizon Oncology Research
Lafayette, Indiana, United States - (and 6 more...)
|
34 |
NCT03149003 |
Recruiting |
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy |
|
- Drug: DSP-7888 Dosing Emulsion
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)
- Overall Survival
- Twelve-month Survival
- (and 5 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03149003 |
BBI-DSP7888-201G |
WIZARD201G |
December 8, 2017 |
December 2019 |
June 2020 |
May 11, 2017 |
March 26, 2018 |
|
- Center for Neurosciences
Tucson, Arizona, United States - Highlands Oncology Group
Fayetteville, Arkansas, United States - University of California Los Angeles Neuro-Oncology (UCLA)
Los Angeles, California, United States - (and 17 more...)
|
35 |
NCT00898755 |
Recruiting |
Collecting and Storing Tissue From Young Patients With Cancer |
|
- Genetic: DNA analysis
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: biologic sample preservation procedure
- (and 2 more...)
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Establishment and banking of cell lines and/or xenografts from pediatric patients with cancer
- Establishment of continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer
- Establishment of transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro
- (and 5 more...)
|
500 |
All |
up to 21 Years (Child, Adult) |
NCT00898755 |
ABTR04B1 COG-ABTR04B1 NCI-2009-00326 |
|
March 2007 |
January 2020 |
January 2020 |
May 12, 2009 |
November 29, 2017 |
|
- Children's Hospital of Alabama at University of Alabama at Birmingham
Birmingham, Alabama, United States - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 41 more...)
|
36 |
NCT01793168 |
Recruiting |
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
- Rare Disorders
- Undiagnosed Disorders
- Disorders of Unknown Prevalence
- (and 260 more...)
|
|
Observational |
|
- Sanford Health
- National Ataxia Foundation
- International WAGR Syndrome Association
- (and 23 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.
|
20000 |
All |
Child, Adult, Senior |
NCT01793168 |
03-10-014 Hypersomnia Foundation National Ataxia Foundation 4p- Support Group CdLS Foundation Hyperacusis Research Limited Kabuki Syndrome Network Kawasaki Disease Foundation Klippel-Feil Syndrome Freedom Leiomyosarcoma Direct Research MSS Support Group ML4 Foundation Stickler Involved People IWSA Soft Bones PWN4PWN aHUS Klippel-Feil Syndrome Alliance American MEN Support Kleine-Levin Syndrome All Things Kabuki WSS Foundation BIVA ABDA PROS Foundation (HLH) |
CoRDS |
July 2010 |
December 2100 |
December 2100 |
February 15, 2013 |
October 2, 2017 |
|
- Sanford Health
Sioux Falls, South Dakota, United States
|
37 |
NCT02085148 |
Recruiting |
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy |
|
- Drug: Regorafenib (BAY73-4506)
- Drug: Vincristine (Cellcristin®)
- Drug: Irinotecan (Irinotecan Cell pharm®)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Safety: Maximum Tolerated Dose
- Safety: Recommended Phase II Dose
- Number of participants with Adverse Events
- (and 10 more...)
|
77 |
All |
6 Months to 18 Years (Child, Adult) |
NCT02085148 |
15906 2013-003579-36 |
|
April 11, 2014 |
October 24, 2019 |
October 24, 2019 |
March 12, 2014 |
April 2, 2018 |
|
- Lyon Cedex, France
- Marseille, France
- Paris, France
- (and 15 more...)
|
38 |
NCT03507491 |
Not yet recruiting New |
Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors |
|
- Drug: Gemcitabine
- Drug: Nab-paclitaxel
|
Interventional |
Phase 1 |
- Emory University
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum dose tolerated of nab-paclitaxel
- Toxicity of nab-paclitaxel
- Antitumor activity of nab-paclitaxel
- (and 2 more...)
|
24 |
All |
6 Months to 30 Years (Child, Adult) |
NCT03507491 |
IRB00098777 |
|
May 2018 |
May 2021 |
May 2022 |
April 25, 2018 |
April 25, 2018 |
|
- Johns Hopkins All Children's Hospital
Saint Petersburg, Florida, United States - Chilldren's Healthcare of Atlanta
Atlanta, Georgia, United States
|
39 |
NCT02574728 |
Recruiting |
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors |
|
- Drug: Sirolimus
- Drug: Celecoxib
- Drug: Etoposide
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in radiographic response to treatment for solid tumors
- Change in radiographic response to treatment for central nervous system (CNS) tumors
- Number of adverse events
|
60 |
All |
12 Months to 30 Years (Child, Adult) |
NCT02574728 |
IRB00082488 |
AflacST1502 |
June 2015 |
June 2020 |
June 2020 |
October 14, 2015 |
March 26, 2018 |
|
- Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, United States - Children's Healthcare of Atlanta, Scottish Rite
Atlanta, Georgia, United States - Children's Mercy Hospital
Kansas City, Missouri, United States
|
40 |
NCT03311334 |
Recruiting |
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors |
- Neoplasms
- Melanoma
- Non Small Cell Lung Cancer
- (and 3 more...)
|
- Drug: DSP-7888 Dosing Emulsion
- Drug: Nivolumab
- Drug: Atezolizumab
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the safety and tolerability of DSP-7888 Dosing Emulsion given intradermally with a checkpoint inhibitor (Nivolumab or Atezolizumab) in adult subjects with advanced solid tumors by assessing dose-limiting toxicities (DLTs)
- Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)
- Duration of response by RECIST
- (and 8 more...)
|
84 |
All |
18 Years and older (Adult, Senior) |
NCT03311334 |
BBI-DSP7888-102CI |
|
December 14, 2017 |
October 2018 |
November 2020 |
October 17, 2017 |
April 5, 2018 |
|
- Gabrail Cancer Center Research
Canton, Ohio, United States
|
41 |
NCT02650401 |
Recruiting |
Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions |
- Solid Tumors
- CNS Tumors
- Neuroblastoma
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Recommended Phase 2 Dose (RP2D)
- Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
- (and 7 more...)
|
190 |
All |
2 Years to 22 Years (Child, Adult) |
NCT02650401 |
RXDX-101-03 |
|
December 2015 |
September 2018 |
March 2019 |
January 8, 2016 |
February 8, 2018 |
|
- Children's Hospital of Orange County
Orange, California, United States - UCSD Rady Children's Hospital
San Diego, California, United States - UCSF Benihoff Children's
San Francisco, California, United States - (and 18 more...)
|
42 |
NCT02750995 |
Recruiting |
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML |
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
|
- Biological: NPMW-peptide vaccine
- Drug: Azacitidine
|
Interventional |
Phase 1 |
- Inge Høgh Dufva
- Technical University of Denmark
- Herlev Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Immunological evaluation
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02750995 |
AZACTA |
AZACTA |
April 2016 |
April 2020 |
September 2020 |
April 26, 2016 |
September 1, 2017 |
|
- Dept of Hematology, Herlev Hospital
Herlev, Denmark
|